American Journal of Cardiology
Volume 99, Issue 10 , Pages 1403-1408 , 15 May 2007

Percutaneous Coronary Revascularization Using a Trilayer Metal Phosphorylcholine-Coated Zotarolimus-Eluting Stent

  • Alexandre Abizaid, MD, PhD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Alexandra J. Lansky, MD

      Affiliations

    • Cardiovascular Research Foundation, New York, New York
    • ,
  • Peter J. Fitzgerald, MD, PhD

      Affiliations

    • Stanford University Medical Center, Palo Alto, California
    • ,
  • Luis Fernando Tanajura, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Fausto Feres, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Rodolfo Staico, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Luiz Mattos, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Andrea Abizaid, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Aurea Chaves, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Marinella Centemero, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Amanda G.M.R. Sousa, MD, PhD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • J. Eduardo Sousa, MD, PhD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, Saõ Paulo, Brazil
    • ,
  • Margo J. Zaugg, BSN

      Affiliations

    • Abbott Laboratories, Abbott Park, Illinois.
    • ,
  • Lewis B. Schwartz, MD

      Affiliations

    • Abbott Laboratories, Abbott Park, Illinois.
    • Corresponding Author InformationCorresponding author: Tel.: 847-936-3104; fax: 847-936-0388.

Received 17 October 2006 ,Revised 21 December 2006 ,Accepted 21 December 2006.

References 

  1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  2. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  3. Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, Münzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation. 2006;114:798–806
  4. Lewis AL, Stratford PW. Phosphorylcholine-coated stents. J Long-Term Effects Med Implants. 2002;12:231–250
  5. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, et al Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288
  6. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F-J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816–2821
  7. Lewis AL, Cumming ZL, Goreish HH, Kirkwood LC, Tolhurst LA, Stratford PW. Crosslinkable coatings from phosphorylcholine-based polymers. Biomaterials. 2001;22:99–111
  8. Lewis AL, Tolhurst LA, Stratford PW. Analysis of phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials. 2002;23:1697–1706
  9. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol. 2001;13:193–201
  10. Kuiper KK, Robinson KA, Chronos NAF, Cui J, Palmer SJ, Nordrehaug JE. Phosphorylcholine-coated stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J. 1998;32:261–268
  11. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 2000;83:338–345
  12. Zheng H, Barragan P, Corcos T, Simeoni J-B, Favereau X, Roquebert P-O, et al. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invasive Cardiol. 1999;11:608–614
  13. Galli M, Bartorelli A, Bedogni F, DeCesare N, Klugmann S, Maiello L, et al Italian BiodivYsio Open Registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invasive Cardiol. 2000;12:452–458
  14. Boland JL, Corbeij HAM, van der Giessen WJ, Seabra-Gomes R, Suryapranata H, Wijns W, et al Multicentre evaluation of the phosphorylcholine-coated BiodivYsio stent in short de novo coronary lesions: the SOPHOS study. Int J Card Interv. 2000;3:215–225
  15. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006;58:437–446
  16. Garcia-Touchard A, Burke SE, Toner JT, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J. 2006;27:988–993
  17. DuVall M, Ji Q, Clifford A, Barry CM, Nowak SA, Sabaj KM, et al ABT-578 elution profile and arterial penetration using the ZoMaxx drug-eluting stent. Am J Cardiol. 2004;94(suppl):223E
  18. Abizaid A. First-in-human clinical results: the TriMaxx and ZoMaxx IVUS trials. Available at www.europcronline.com. Accessed January 2007.
  19. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, et al Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192–195
  20. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–2011
  21. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, et al The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46:253–260
  22. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroInt. 2005;2:157–164
  23. Aoki J, Ong ATL, Abizaid A, den Heijer P, Bonnier H, McClean DR, et al One-year clinical outcome of various doses and pharmacokinetic release of paclitaxel eluted from an erodable polymer—insights from the Paclitaxel In-stent Controlled Elution Study (PISCES). EuroInt. 2005;2:165–172
  24. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005;112:2833–2839
  25. Kandzari DE. ENDEAVOR Overview of ABT-578/PC/Cobalt Technology and Clinical Trial Program. Available at: www.tct.md 2006. Accessed January 2007.

PII: S0002-9149(07)00256-1

doi: 10.1016/j.amjcard.2006.12.064

American Journal of Cardiology
Volume 99, Issue 10 , Pages 1403-1408 , 15 May 2007

Article Tools

* Image Usage & Resolution